Harrow, Inc. (NASDAQ:HROW)
| Market Cap | 1.14B-23.4% |
| Revenue (ttm) | 275.59M+21.1% |
| Net Income | -37.23M-264.0% |
| EPS | -0.99-231.3% |
| Shares Out | 37.28M |
| PE Ratio | n/a |
| Forward PE | 13.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,701.891 |
| Open | 30.35 |
| Previous Close | 30.62 |
| Day's Range | 30.01 - 30.50 |
| 52-Week Range | 28.54 - 54.85 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 66.50(+118.32%) |
| Earnings Date | Nov 9, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About HROW
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$HROW stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in HROW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HROW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HROW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
HROW Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Branded | $56.10M | 44.26% |
| VEVYE | $29.39M | 23.18% |
| IHEEZO | $15.62M | 12.32% |
| Compounding | $14.56M | 11.48% |
| Other branded products | $11.01M | 8.68% |
| Other revenues | $90.00K | 0.07% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New HROW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HROW from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in HROW
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $36.96M |
| IWMiShares Russell 2000 ETF | $25.99M |
| VXFVanguard Extended Market ETF | $14.22M |
| IWOiShares Russell 2000 Growth ETF | $9.23M |
| DFASDimensional - US Small Cap ETF | $8.34M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $8.10M |
Estimated from each fund’s disclosed top holdings × AUM
HROW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from HROW’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score